https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Approves 3-Month Leuprolide Mesylate 21 mg Formulation for Advanced Prostate Cancer

FDA Approves 3-Month Leuprolide Mesylate 21 mg Formulation for Advanced Prostate Cancer

The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced prostate cancer.

administrator

Related Articles